Pennsylvania v. Altoona Hospital and Bon Secours Holy Family Regional Health System (Oct. 2004)
Altoona Hospital and Bon Secours merger allowed as long as the merged hospital system follows the requirements outlined in the consent decree.
Pennslyvania v. Conemaugh Memorial and UPMC Lee (Jul. 2005)
Consent decree filed by Pennsylviana AG, allowing Conemaugh and UPMC Lee merger as long as certain requirements are followed.
In the Matter of GlaxoSmithKline, PLC (Augmentin)
States alleged that GlaxoSmithKline fraudulently obtained patent protection for Augmentin and then delayed generic entry through sham patent litigation. Through this conduct, GlaxoSmithKline unlawfully maintained its monopoly over Augmentin. A $3.5 million multistate settlement for state proprietary claims was entered into by the participating states and GlaxoSmithKline.
In Re Relafen Antitrust Litigation
States sued manufacturer of antidepressant Relafen, alleging patent misuse and sham litigation designed to prevent generic entry. Parties settled the state proprietary claims for $10 million.
Texas v. Zurich American Insurance Company (In re Insurance Brokerage Antitrust Lit. (D.C. No. 04-cv-05184, D.N.J.)
Zurich settled claims involving payment of contingent commissions and submission of false bids for insurance coverage.
Maryland v. SmithKline Beecham Corp., No. 2:06-cv-01298-JP (E.D.Pa Mar. 27, 2006)
States sued manufacturer of antitdepressant Paxil, alleging patent misuse and sham litigation designed to prevent generic entry. Parties settled for $14 million.
U.S. and Pennsylvania v. USA Waste Services, Inc. (W.D.Pa. 8/22/1997)
Merger of largest and third-largest waste hauling companies in the U.S. Joint complaint and settlement filed, requiriing divestiture of landfill sites near Pittsburgh.
Merger of CorestatesFinancial Corp./Meridian Bancorp
Joint investigation with Department of Justice of merger of two banks. Merger approved with divesitutres.
Connecticut v. Mylan Laboratories, Inc. (In re Lorazepam & Clorazepate Antitrust Litigation), MDL No. 1290 (D.D.C. June 15, 2000) 205 F.R.D. 369 (D.D.C. 2002); No. 98 CV 3115 (D.D.C. 2000) – complaint
Plaintiff States alleged that Mylan Laboratories, Inc.(Mylan) and other drug companies entered into illegal agreements to monopolize the market for certain generic anti-anxiety drugs.
Pennsylvania Settlement with United Chair Company
Defendant furniture manufacturer settled claims of bid-rigging on contracts with the state.
